N
CRVS icon

Natixis’s Corvus Pharmaceuticals CRVS Stock Holding History

Natixis’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-800
Closed -$1.41K – 1044
2023
Q4 		$1.41K Hold
800
– – ﹤0.01% 983
2023
Q3 		$1.17K Hold
800
– – ﹤0.01% 927
2023
Q2 		$1.83K Buy
+800
New +$1.66K ﹤0.01% 965
2021
Q3 		– Sell
-27,900
Closed -$74K – 1211
2021
Q2 		$74K Buy
27,900
+11,400
+69% +$31.4K ﹤0.01% 838
2021
Q1 		$51K Buy
+16,500
New +$59.6K ﹤0.01% 1051

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TL
TowerView LLC New York $155M AUM 30.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return